Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323569 | 0.92 | CYP3A4 (0.44) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL23325421 | 0.92 | HRH3 (0.39) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL23323478 | 0.92 | CYP3A4 (0.39) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL25884737 | 0.90 | HRH3 (0.36) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL23323567 | 0.90 | CYP2D6 (0.39) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL23324887 | 0.85 | HRH3 (0.43) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL23323571 | 0.83 | HRH3 (0.42) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL21739865 | 0.80 | CYP3A4 (0.53) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL25884739 | 0.80 | HRH3 (0.31) | HRH3 | |
| SCHEMBL25953982 | 0.78 | TSHR (0.40) | HRH3CYP3A4CYP2C9CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HRH3 3696/4885CYP3A4 3780/4885CYP2C9 3961/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HRH3 3696/4885CYP3A4 3780/4885CYP2C9 3961/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HRH3 3890/4885CYP3A4 4873/4885CYP2C9 4876/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HRH3 3696/4885CYP3A4 3780/4885CYP2C9 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.